Novel vaccine approach to human cytomegalovirus found effective

September 18, 2013, UC Davis

An experimental vaccine against human cytomegalovirus (CMV) infection, which endangers the developing fetus, organ transplant recipients, patients with HIV and others who have a weakened immune system, proved safe and more effective than previous vaccines developed to prevent infection by the ubiquitous virus.

The first-of-its-kind approach to preventing human CMV infection, developed by a team of scientists at UC Davis and the University of Alabama, Birmingham, induced broader immunological protection in an animal model. The research study will appear in the November issue of the Journal of Virology.

Development of a CMV vaccine has been ranked as the highest priority by the Institute of Medicine, an independent agency of the National Academy of Science, because of "the lives it would save and the disabilities it would prevent," according to the CDC.

"We've completed the first step in developing a vaccine to protect people against CMV by interfering with the virus's attempts to enter and infect cells in the body," said Peter A. Barry, a professor of pathology and laboratory medicine at the UC Davis School of Medicine and lead author of the study. Barry also is a member of the faculty at the Center for Comparative Medicine and a staff scientist at the California National Primate Research Center at UC Davis.

About CMV

CMV is a type of herpes virus that is spread through close contact with the saliva, urine or other body fluids of a person infected with the virus. Most CMV infections are not diagnosed because the virus typically causes few, if any, symptoms. As a result, most people infected with CMV are unaware that they harbor the virus—a condition that is of most concern among pregnant women, who are at risk for transmitting the virus to the fetus. Children who are congenitally infected with CMV may have cognitive and other developmental disabilities, including hearing loss and blindness.

CMV is the most common viral cause of in the U.S. About 1 in 150 children in the U.S. is born with congenital CMV. While most of these children will not develop symptoms or problems, about 1 of every 5 children with congenital CMV infection—a total of 5,000 children each year—will develop hearing loss or due to the infection, according to the U.S. Centers for Disease Control and Prevention (CDC).

CMV also can infect animals, including rodents and rhesus macaque monkeys and other non-human primates. However, the CMV species found in animals differs from human CMV and has not been reported to cause human disease.

A persistant virus

Because so many previous vaccine approaches failed to provide complete protection against CMV infection, Barry and his collaborators adopted an "out-of-the-box" approach when designing the new vaccine.

They focused on CMV's ability to gain a lifelong foothold in the body, a stage of the virus's life cycle that no other research lab has targeted in research on potential CMV vaccines.

"CMV is not like the influenza virus, which our immune systems can successfully clear from our bodies. CMV infection is persistent," Barry said. "Once you're infected, you're always infected."

The virus's persistence and ability to infect individuals without creating obvious symptoms of infection help explain why CMV can be found in 50 to 80 percent of people under the age of 40.

Targeting a master immune system regulator

The key to CMV's persistence, Barry and his colleagues theorized, is interleukin-10 (IL-10), the master regulator of the immune system, which works to rein in an over-zealous immune response to an invading pathogen.

Barry previously discovered that early in its evolutionary history CMV hijacked IL-10 and incorporated its genes into the virus's own DNA code. As a result, CMV can manipulate the body's normal immune response to the virus.

In developing their novel vaccine strategy, the researchers focused on neutralizing CMV's own IL-10 so that the immune defense system was again capable of responding vigorously and effectively to the presence of the virus.

"We found that the animals did not become infected because, as a result of the vaccine, their immune systems generated neutralizing antibodies that prevented CMV from entering and infecting connective tissue cells, epithelial cells and other major cell types that the virus targets," said Barry.

"The vaccine also created 'immunological memory,' which enables the to respond quickly and effectively whenever CMV re-infection occurs," he said.

Future studies

Based on these positive results, the researchers will evaluate the vaccine's effectiveness and safety in an experimental setting that allows CMV-infected and vaccinated animals to interact, transmitting the virus as it typically would in the wild. By comparing rates of CMV infection in the vaccinated and non-vaccinated animals, the research team will determine whether the vaccine alters the natural course of CMV infection and should be considered for clinical studies with humans.

Explore further: AIDS vaccine candidate appears to completely clear virus from the body

Related Stories

AIDS vaccine candidate appears to completely clear virus from the body

September 11, 2013
An HIV/AIDS vaccine candidate developed by researchers at Oregon Health & Science University appears to have the ability to completely clear an AIDS-causing virus from the body. The promising vaccine candidate is being developed ...

How a virus might make you diabetic later in life

August 27, 2012
Cytomegalovirus (CMV) is one of the viruses that most infected people carry without ill effects. Once infected you are infected for life and, although it normally is dormant, it can become active again at any point in time. ...

Researchers show long-term consequences of chronic virus infection

August 16, 2012
The cytomegalovirus (CMV) is a member of the herpesvirus family. Although most people carry CMV for life, it hardly ever makes them sick. Researchers from the Helmholtz Centre for Infection Research and from the USA have ...

Test approved to help treat common infection in transplant patients

July 5, 2012
(HealthDay) -- The first DNA test to help doctors treat a common viral infection in people who have had a solid organ transplant has been approved by the U.S. Food and Drug Administration.

CMV-linked eye infections ID'd in patients without HIV

March 18, 2013
(HealthDay)—Cytomegalovirus (CMV)-associated posterior uveitis or panuveitis can develop in patients without HIV infection, most of whom have evidence of compromised immune function, according to a study published online ...

Study advances fight against leading infectious cause of congenital birth defects

March 13, 2013
A virus most people probably have never heard of, but that the majority of us carry, is the No. 1 infectious cause of congenital birth defects in the U.S. today. Because of cytomegalovirus (CMV) infection during in utero ...

Recommended for you

HIV-1 genetic diversity is higher in vaginal tract than in blood during early infection

January 18, 2018
A first-of-its-kind study has found that the genetic diversity of human immunodeficiency virus type 1 (HIV-1) is higher in the vaginal tract than in the blood stream during early infection. This finding, published in PLOS ...

War in Ukraine has escalated HIV spread in the country: study

January 15, 2018
Conflict in Ukraine has increased the risk of HIV outbreaks throughout the country as displaced HIV-infected people move from war-affected regions to areas with higher risk of transmission, according to analysis by scientists.

Researchers offer new model for uncovering true HIV mortality rates in Zambia

January 12, 2018
A new study that seeks to better ascertain HIV mortality rates in Zambia could provide a model for improved national and regional surveillance approaches, and ultimately, more effective HIV treatment strategies.

New drug capsule may allow weekly HIV treatment

January 9, 2018
Researchers at MIT and Brigham and Women's Hospital have developed a capsule that can deliver a week's worth of HIV drugs in a single dose. This advance could make it much easier for patients to adhere to the strict schedule ...

New long-acting, less-toxic HIV drug suppresses virus in humanized mice

January 8, 2018
A team of Yale researchers tested a new chemical compound that suppresses HIV, protects immune cells, and remains effective for weeks with a single dose. In animal experiments, the compound proved to be a promising new candidate ...

Usage remains low for pill that can prevent HIV infection

January 8, 2018
From gritty neighborhoods in New York and Los Angeles to clinics in Kenya and Brazil, health workers are trying to popularize a pill that has proven highly effective in preventing HIV but which—in their view—remains woefully ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.